Covid-19 Clinical Trial
— IMT-ReCovOfficial title:
Effects of Inspiratory Muscle Training After Covid-19
Initially, it was suspected that Covid-19 would primarily affect the airways, but several studies have now shown that it is a disease with multisystem manifestations. Covid-19 has the potential to affect physical, cognitive, and psychological functions in multiple ways. It has been clear that a significant proportion of patients with Covid-19 develop long-term symptoms. The term post-acute Covid-19 syndrome (PACS) is now used to describe the wide range of prolonged symptoms following the infection. Patients who have been in hospital for Covid-19 for a long time may need specialized rehabilitation, however, also non-hospitalized patients with mild symptoms may need specific rehabilitation to be able to meet the complex symptoms and problems that may arise. Previous studies on the recovery and rehabilitation after other coronavirus shows the importance to develop tailored interventions so that these patients receive appropriate rehabilitation The aim of this study is to evaluate the effects of inspiratory muscle training on adult patients with PACS and decreased respiratory muscle strength. A randomized controlled trial will be used. A total of 90 adult patients with PACS and 80 % or less of predicted value in inspiratory muscle strength (maximal inspiratory pressure) will be eligible for enrollment. Patients will be randomized either to an intervention group or a control group. The intervention will consist of inspiratory muscle training performed twice daily for 8 weeks. This will be combined with an 8-week physical exercise training program. The control group will perform the same physical exercise training according to standard care. All measurements will be performed at baseline and after 8 weeks. Primary outcome is maximal inspiratory pressure. Secondary outcomes are: Maximal expiratory pressure, pulmonary function, physical capacity, physical activity, respiratory status and symptoms, health-related quality of life, work ability, fatigue, self-reported outcome measure of physical function and voice function. Covid-19 has the potential to affect physical, cognitive, and psychological functions in multiple ways and lead to a negative impact on quality of life in the long-term perspective. Therefore, development of a rehabilitation program with specific tailored interventions will be necessary to improve physical and psychological function, as well as health-related quality of life and work ability.
Status | Recruiting |
Enrollment | 90 |
Est. completion date | December 2024 |
Est. primary completion date | June 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Adult patients (=18 years) who have undergone Covid-19 and have 80% or less of the lower limit of predicted value in maximal inspiratory pressure (MIP). Exclusion Criteria: - Physical och cognitive dysfunction which makes it impossible to carry out measurements and interventions. Already on-going intervention with inspiratory muscle training. |
Country | Name | City | State |
---|---|---|---|
Sweden | Karolinska University Hospital | Stockholm |
Lead Sponsor | Collaborator |
---|---|
Karolinska Institutet | Karolinska University Hospital |
Sweden,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in Maximal Inspiratory Pressure (MIP) | Change in MIP measured in cmH20 with a Respiratory Pressure Meter (Micro RPM) | Measured before and after the intervention period of 8 weeks to detect a change | |
Secondary | Change in Maximal Expiratory Pressure (MEP) | Change in MEP measured in cmH20 with a Respiratory Pressure Meter (Micro RPM) | Measured before and after the intervention period of 8 weeks to detect a change | |
Secondary | Change in Lung function | Change in Forced Expiratory Volume in one second (FEV1), Forced Vital Capacity (FVC), Peak Expiratory Flow (PEF) and FEV1/FVC measured with spirometry. FEV1 and FVC are measured in liters (l) and PEF in liter/second (l/s). | Measured before and after the intervention period of 8 weeks to detect a change | |
Secondary | Change in walking distance during 6 minute walk test | Change in walking distance measured in meters during 6 minutes walk test (6MWT) | Measured before and after the intervention period of 8 weeks to detect a change | |
Secondary | Change in oxygen saturation during 6 minute walk test | Change in the lowest oxygen saturation level measured in percentage (%) with pulse oximetry during 6 minute walk test | Measured before and after the intervention period of 8 weeks to detect a change | |
Secondary | Change in oxygen desaturation during 6 minute walk test | Change in drop in percentage points in oxygen saturation during 6 minute walk test. The drop in percentage points is calculated by subtracting the oxygen level at rest before the test with the lowest level during the test. | Measured before and after the intervention period of 8 weeks to detect a change | |
Secondary | Change in dyspnea during 6 minute walk test | Change in perceived dyspnea measured with Borg Category-Ratio scale (Borg CR-10) at the end of 6 minute walk test. Borg CR-10 ranging between 0-10. The higher the score, the higher the dyspnea. | Measured before and after the intervention period of 8 weeks to detect a change | |
Secondary | Change in leg fatigue during 6 minute walk test | Change in perceived leg fatigue measured with Borg CR-10 at the end of 6 minute walk test. Borg CR-10 ranging between 0-10. The higher the score, the higher the leg fatigue. | Measured before and after the intervention period of 8 weeks to detect a change | |
Secondary | Change in exertion during 6 minute walk test | Change in perceived exertion measured with Borg Rating of Perceived Exertion (Borg RPE) at the end of 6 minutes walk test. Borg RPE ranging between 6-20. The higher the score, the higher the exertion. | Measured before and after the intervention period of 8 weeks to detect a change | |
Secondary | Change in heart rate during 6 minute walk test | Change in the highest heart rate measured in beats per minute with pulse oximeter during 6 minute walk test | Measured before and after the intervention period of 8 weeks to detect a change | |
Secondary | Change in number of stands in 30 seconds | Change in number of stands measured during chair stand test after 30 seconds | Measured before and after the intervention period of 8 weeks to detect a change | |
Secondary | Change in number of stands in 60 seconds | Change in number of stands measured during chair stand test after 60 seconds | Measured before and after the intervention period of 8 weeks to detect a change | |
Secondary | Change in oxygen saturation during chair stand test | Change in lowest oxygen saturation level measured in percentage (%) with pulse oximetry during chair stand test (60 s) | Measured before and after the intervention period of 8 weeks to detect a change | |
Secondary | Change in oxygen desaturation during chair stand test | Change in drop in percentage points in oxygen saturation during chair stand test. The drop in percentage points is calculated by subtracting the oxygen level at rest before the test with the lowest level during the test. | Measured before and after the intervention period of 8 weeks to detect a change | |
Secondary | Change in dyspnea during chair stand test | Change in perceived dyspnea measured with Borg CR-10 at the end of chair stand test (60 s). Borg CR-10 ranging between 0-10. The higher the score, the higher the dyspnea. | Measured before and after the intervention period of 8 weeks to detect a change | |
Secondary | Change in leg fatigue during chair stand test | Change in perceived leg fatigue measured with Borg CR-10 at the end of chair stand test (60 s). Borg CR-10 ranging between 0-10. The higher the score, the higher the leg fatigue. | Measured before and after the intervention period of 8 weeks to detect a change | |
Secondary | Change in exertion during chair stand test | Change in perceived exertion measured with Borg RPE scale at the end of chair stand test (60 s). Borg RPE scale ranging between 6-20. The higher the score, the higher the exertion. | Measured before and after the intervention period of 8 weeks to detect a change | |
Secondary | Change in heart rate during chair stand test | Change in the highest heart rate measured in beats per minute with pulse oximeter during chair stand test (60 s). | Measured before and after the intervention period of 8 weeks to detect a change | |
Secondary | Change in Dyspnea - mMRC | Measured with Modified Medical Research Council (mMRC), which is a self-rating tool to measure the degree of disability that breathlessness postures on daily physical activities on a scale from 0 to 4. 0, no breathlessness except on strenuous exercise; 1, shortness of breath when hurrying on the level or walking up a hill; 2, walks slower than people of same age on the level because of breathlessness; 3, stops for breath when walking at their own pace on the level; and 4, Breathless when washing or getting dressed. | Measured before and after the intervention period of 8 weeks to detect a change | |
Secondary | Change in Health-related quality of life (HRQoL) | Measured with EuroQOL 5 dimensions questionnaire (EQ-5D-5L), which is an instrument that evaluates the generic quality of life. EQ-5D includes a descriptive system, which comprises 5 dimensions of health: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. A descriptive index-score between 0-1, higher score indicates higher HRQoL. EQ-5D also includes a visual analog scale (VAS), which records the respondent's self-rated health status on a graduated (0-100) scale, with higher scores for higher HRQoL. | Measured before and after the intervention period of 8 weeks to detect a change | |
Secondary | Change in Work ability | Measured with Work Ability Index (WAI), which is a self assessment tool consisting of 7 items. Scores ranging from 7-49. Higher score indicates higher work ability. | Measured before and after the intervention period of 8 weeks to detect a change | |
Secondary | Change in Fatigue | Measured with Fatigue Severity Scale (FSS), which is a 9-item scale that measures the severity of fatigue and its effect on a person's activities and lifestyle in patients with a variety of disorders. Total score ranging from 9-63. The higher the score, the more severe the fatigue is. | Measured before and after the intervention period of 8 weeks to detect a change | |
Secondary | Change in self-reported outcome measure of physical function | Measured with Patient Specific Functional Scale (PSFS), a questionnaire that can be used to quantify activity limitation and measure functional outcome for patients. Patients are asked to identify three to five important activities they are unable to perform or are having difficulty with because of their problem. In addition to identifying the activities, patients are asked to rate, on a scale ranging from 0-10, the current level of difficulty associated with each activity. The higher the score, the less difficulty to perform the activity. | Measured before and after the intervention period of 8 weeks to detect a change | |
Secondary | Change in Voice function | Measured with a self-assessment form of voice function (SOFT) and a standardized voice recording in a studio. Total score of SOFT ranging between 0-3. Higher score means more difficulties. | Measured before and after the intervention period of 8 weeks to detect a change | |
Secondary | Change in Respiratory symptoms | Respiratory rate visually measured during 60 seconds at rest and self-reported symptoms including cough, mucus and chest tightness | Measured before and after the intervention period of 8 weeks to detect a change | |
Secondary | Change in Physical activity | Measured with Frändin/Grimby activity scale, which is a self-assessment scale about current levels of physical activity, ranging from 1 to 6. The higher the score, the higher level of physical activity. | Measured before and after the intervention period of 8 weeks to detect a change |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT06065033 -
Exercise Interventions in Post-acute Sequelae of Covid-19
|
N/A | |
Completed |
NCT06267534 -
Mindfulness-based Mobile Applications Program
|
N/A | |
Completed |
NCT05047601 -
A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection
|
Phase 2/Phase 3 | |
Recruiting |
NCT04481633 -
Efficacy of Pre-exposure Treatment With Hydroxy-Chloroquine on the Risk and Severity of COVID-19 Infection
|
N/A | |
Recruiting |
NCT05323760 -
Functional Capacity in Patients Post Mild COVID-19
|
N/A | |
Completed |
NCT04537949 -
A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults
|
Phase 1/Phase 2 | |
Completed |
NCT04612972 -
Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) to Prevent COVID-19 in Healthy Adult Population In Peru Healthy Adult Population In Peru
|
Phase 3 | |
Recruiting |
NCT05494424 -
Cognitive Rehabilitation in Post-COVID-19 Condition
|
N/A | |
Active, not recruiting |
NCT06039449 -
A Study to Investigate the Prevention of COVID-19 withVYD222 in Adults With Immune Compromise and in Participants Aged 12 Years or Older Who Are at Risk of Exposure to SARS-CoV-2
|
Phase 3 | |
Enrolling by invitation |
NCT05589376 -
You and Me Healthy
|
||
Completed |
NCT05158816 -
Extracorporal Membrane Oxygenation for Critically Ill Patients With COVID-19
|
||
Recruiting |
NCT04341506 -
Non-contact ECG Sensor System for COVID19
|
||
Completed |
NCT04384445 -
Zofin (Organicell Flow) for Patients With COVID-19
|
Phase 1/Phase 2 | |
Completed |
NCT04512079 -
FREEDOM COVID-19 Anticoagulation Strategy
|
Phase 4 | |
Completed |
NCT05975060 -
A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants.
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT05542862 -
Booster Study of SpikoGen COVID-19 Vaccine
|
Phase 3 | |
Withdrawn |
NCT05621967 -
Phonation Therapy to Improve Symptoms and Lung Physiology in Patients Referred for Pulmonary Rehabilitation
|
N/A | |
Terminated |
NCT05487040 -
A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease
|
Phase 1 | |
Terminated |
NCT04498273 -
COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80
|
Phase 3 | |
Active, not recruiting |
NCT06033560 -
The Effect of Non-invasive Respiratory Support on Outcome and Its Risks in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2)-Related Hypoxemic Respiratory Failure
|